Osborne Clarke completes new deal in life sciences sector, supporting Creo Medical Group to raise funds and sell its remaining stake in Creo Medical S.L.

International legal practice Osborne Clarke has advised longstanding client, Creo Medical Group, to raise new funds and move towards selling its remaining 49 per cent stake in Creo Medical S.L. 

Creo Medical Group is a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients.

Osborne Clarke advised the company on a share placing, issuing convertible loan notes, and the planned sale of its remaining 49 per cent stake in Creo Medical S.L. This follows Osborne Clarke's previous support given to Creo Medical Group, having advised on its five previous fundraises and the divestment of 51 per cent of Creo Medical S.L. to endoscopic medical device manufacturer Micro-Tech in October 2024.

Our work on this deal underlines Osborne Clarke’s strength in advising innovative life sciences businesses on complex corporate matters, bringing together deep sector insight with capital markets expertise to help clients deliver on their growth plans.

Mark Wesker, Partner, Osborne Clarke. 

The Osborne Clarke Corporate team was led by partner Mark Wesker and supported by associate director Stuart Miller and associate Elizabeth Britchford.